The Role of Nanotherapeutic Agents in Hematology and Related Diseases
- By Veena Ganti1
-
View Affiliations Hide Affiliations1 William Mason High School, 6100 Mason Montgomery Rd, Mason, OH 45040,United States
- Source: Nanotherapeutic Strategies and New Pharmaceuticals (Part 1) , pp 56-66
- Publication Date: November 2021
- Language: English
The Role of Nanotherapeutic Agents in Hematology and Related Diseases, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789815036695/chapter3-1.gif
Hematological anomalies are becoming more prevalent in the world and are comprised of blood-related diseases. They either disrupt normal blood circulation or reduce the blood volume and, consequently, death. Therapies are available to treat and alleviate these diseases, but they adversely interact with other organs/tissues to provoke them. To avoid such adverse scenarios, NT graced medicine to deliver therapeutic agents in nanocarriers that are engineered to transport them to their target site, averting untoward effects and functioning for a long time. In this chapter, we will be highlighting the role of NT in the treatment of hematological and other related diseases.
-
From This Site
/content/books/9789815036695.chapter3dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
